Biogen Inc.’s Alzheimer’s drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on July 15 with some large hospitals declining to use Aduhelm and health insurers delaying a decision while awaiting coverage terms from Medicare.
The U.S. government started a review process for national Medicare coverage of Biogen Inc.’s Alzheimer’s drug Aduhelm that was approved during June 2021 by the country’s health regulator.
The Centers for Medicare & Medicaid Services (CMS) announced that ClosedLoop.ai was selected the winner and Geisinger the runner-up in the agency’s Artificial Intelligence Health Outcomes Challenge.
Prescription drug prices dropped 1 percent in 2018 – the first time such a drop has occurred in the United States in 45 years – driven primarily by a greater reliance on generic drugs and much slower increases in branded drugs, according to a government study.
Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).
The U.S. Centers for Medicare and Medicaid Services finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc. and Novartis AG.
HHS announced its new price transparency rules for direct-to-consumer TV ads. Now the industry has to sort out what to do about them.
Enrollments in healthcare plans for 2019 through the Federal Obamacare marketplace dropped marginally by 300,000 from 2018, according to U.S. government figures.
NEW YORK, March 22, 2019 /PRNewswire/ — A leading quality rating for the nation’s hospitals appears not to adequately account for the risks of undergoing certain procedures at certain hospitals, particularly joint replacement surgery, according to a new study by researchers at Hospital for Special Surgery (HSS) in New York City. The study, reported in the […]
U.S. health spending is expected to grow at an average rate of 5.5 percent yearly from 2018 over the next decade and will reach nearly $6 trillion by 2027 as more people become eligible for Medicare.